Research On Business Performance Evaluation Of H Biopharmaceutical Company Based On Entropy Weight And Fuzzy Comprehensive Evaluation

With the constant improvement of China's market economy and the rapid development of economic globalization,enterprises need a reasonable performance evaluation system to scientifically evaluate their own business performance in the face of external severe living environment and multi-level market demands and to deal with this complex situation from strategic height.In 2010,the biological industry was recognized by the State Council as one of the seven strategic emerging industries.The biopharmaceuticals industry as the main application field of biotechnology has also become China's key supporting industry in the future,and turned into the focus of a new round of development competition in the world.The terminals of the biopharmaceutical industry are major biopharmaceutical companies.The performance of the companies directly reflects the development of the biopharmaceutical industry.The traditional business performance evaluation mainly focuses on the financial aspects.For the talented and capital-intensive and industry-specific biopharmaceutical companies,traditional performance evaluation has obviously failed to meet the requirements of the development of biopharmaceutical companies in the new era.In order to evaluate scientifically and comprehensively the operational performance of biopharmaceutical companies,this thesis first elaborates on the meanings of the evaluation of business performance and enterprise operating performance,and then systematically reviews the main methods of enterprise performance evaluation and related theories of operating performance evaluation,and describe H biopharmaceutical company's company profile and its operating status in detail.According to the country's policy guidelines for strategic emerging industries,we believes that the positioning of the H biopharmaceutical company's business objectives should focus on the emerging and leading ability of the industries it operates,as well as the ability of sustainable and economic development,we called,strategic;emphasis on the company's core competitiveness comes from major technological innovation capabilities,and the formation of this core competitiveness must follow the rules of the development of circular economy.Based on this,combined with the principle of selection of operating performance evaluation indicators,21 evaluation indicators were selected from the seven aspects of profitability,solvency,operational capacity,development capacity,competitiveness,R&D and innovation capabilities,and social contribution capabilities for H Biopharmaceuticals company's operating performance evaluating.Among them,profitability,solvency and operational ability are evaluated in terms of financial performance;development and competitiveness are indicative of strategic evaluation;the evaluation of R&D and innovation capabilities represent the emerging ability;circular economy evaluation is focused on evaluation of social contribution capability.Finally,the entropy weight method was used to determine the weights and the fuzzy comprehensive evaluation method was used for comprehensive evaluation.Then the main problems in the H biopharmaceutical companies were discovered,and specific countermeasures and suggestions on these specific issues were proposed in order to help H biopharmaceutical companies to overcome all difficulties in the face of development challenge and to achieve its sustainable and healthy development.